DMII Stock Forecast: Drugs Made In America Acquisition II Corp. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 19 Sept 2026 — in the lower half.
DMII stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Drugs Made In America Acquisition II Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (75): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (8): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
DMII stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on DMII, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DMII appears on the weeks it earns a place.
DMII vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
DMII analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Drugs Made In America Acquisition II Corp. (DMII) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 35.1×
- Price / sales
- —
- Price / book
- 1.3×
- EV / EBITDA
- −349.5×
Cheaper than 21% of US stocks
Cheaper than 63% of US stocks
Cheaper than 98% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 32% of US stocks
Higher than 30% of US stocks
- Return on equity
- 0.9%
- Return on assets
- 0.8%
- Dividend yield
- —
Higher than 45% of US stocks
Higher than 48% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
Drugs Made In America Acquisition II Corp. (DMII) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Drugs Made In America Acquisition II Corp. has a market value of $647.8M and an enterprise value of $648.1M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: $13.0M.
Free cash flow in the twelve months to 30 June 2026: −$1.3M.
Trailing P/E: 35.1×.
Drugs Made In America Acquisition II Corp. employs 0 people.
Data provided by Twelve Data
DMII vs competitors
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| DMIIDrugs Made In America Acquisition II Corp. | $647.8M | 27 |
| CCXIChurchill Capital Corp. XI | $718.5M | 9 |
| BBCQPasqal Holding SAS | $732.5M | — |
| EVACEQV Ventures Acquisition Corp. II | $602.0M | 35 |
| BCSSBain Capital GSS Investment Corp. | $600.9M | 28 |
| CXIIChurchill Capital Corp. XII | $591.3M | 9 |
| CEPFCantor Equity Partners IV, Inc. | $590.9M | 28 |
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Drugs Made In America Acquisition II Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about DMII stock
How does Ticker Nerd's model rank DMII?
As at 19 Sept 2026, Drugs Made In America Acquisition II Corp. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (75 of 100).
What is the DMII stock forecast for 2030?
No analyst covering Drugs Made In America Acquisition II Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DMII are extrapolating price history, which says nothing about the business.
What does Drugs Made In America Acquisition II Corp. do?
Drugs Made In America Acquisition II Corp. is a blank check company focused on identifying and completing a business combination with one or more businesses in the pharmaceutical sector.
About Drugs Made In America Acquisition II Corp.
Drugs Made In America Acquisition II Corp. is a blank check company focused on identifying and completing a business combination with one or more businesses in the pharmaceutical sector. As a special purpose acquisition company, it does not operate a traditional commercial business and instead serves as a vehicle for mergers, share exchanges, asset acquisitions, share purchases, recapitalizations, reorganizations, or similar transactions. The company’s stated focus includes evaluating targets connected to pharmaceuticals and related healthcare activities, with an emphasis on domestic drug manufacturing and supply-chain resilience. Incorporated in 2024 and headquartered in New York, Drugs Made In America Acquisition II Corp. plays a market role as a capital-raising and acquisition platform for private operating companies seeking access to public markets.
CEO Ms. Lynn Stockwell · United States